The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Open accessAbstract
The immune system has many sophisticated mechanisms to balance an extensive immune response. Distinct immunosuppressive cells could protect from excessive tissue damage and autoimmune disorders. Tumor cells take an advantage of those immunosuppressive mechanisms and establish a strongly immunosuppressive tumor microenvironment (TME), which inhibits antitumor immune responses, supporting the disease progression. Myeloid-derived suppressor cells (MDSC) play a crucial role in this immunosuppressive TME. Those cells represent a heterogeneous population of immature myeloid cells with a strong immunosuppressive potential. They inhibit an antitumor reactivity of T cells and NK cells. Furthermore, they promote angiogenesis, establish pre-metastatic niches, and recruit other immunosuppressive cells such as regulatory T cells. Accumulating evidences demonstrated that the enrichment and activation of MDSC correlated with tumor progression, recurrence, and negative clinical outcome. In the last few years, various preclinical studies and clinical trials targeting MDSC showed promising results. In this review, we discuss different therapeutic approaches on MDSC targeting to overcome immunosuppressive TME and enhance the efficiency of current tumor immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Chalmin, F., Ladoire, S., Mignot, G., Vincent, J., Bruchard, M., Remy-Martin, J.-P., Boireau, W., Rouleau, A., Simon, B., Lanneau, D., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40483 · Cited by 998
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Condamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts
Peinado, H., Lavotshkin, S., & Lyden, D. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.01.002 · Cited by 654
Hossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0036 · Cited by 588
Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., & Middleton, G. W. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1028-0 · Cited by 575
Mirza, N., Fishman, M., Fricke, I., Dunn, M., Neuger, A. M., Frost, T. J., Lush, R. M., Antonia, S., & Gabrilovich, D. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1690 · Cited by 564
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
The Biology of Cancer Exosomes: Insights and New Perspectives
Ruivo, C. F., Adem, B., Silva, M., & Melo, S. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0994 · Cited by 538
IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice
Bronte, V., Serafini, P., De Santo, C., Marigo, I., Tosello, V., Mazzoni, A., Segal, D. M., Staib, C., Lowel, M., Sutter, G., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.270 · Cited by 513
Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0733 · Cited by 500
Myeloid-Derived Suppressor Cells
(2015) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482
Immune surveillance: a balance between protumor and antitumor immunity
Ostrand-Rosenberg, S. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.007 · Cited by 480
Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., & Linehan, D. C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.3.1746 · Cited by 450
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. (2016) · Vaccines · doi:10.3390/vaccines4040036 · Cited by 438
Self-citationMechanism of All- Trans Retinoic Acid Effect on Tumor-Associated Myeloid-Derived Suppressor Cells
Nefedova, Y., Fishman, M., Sherman, S., Wang, X., Beg, A. A., & Gabrilovich, D. I. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2593 · Cited by 423
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
2011: the immune hallmarks of cancer
Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0968-0 · Cited by 415
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Lesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Self-citationMeyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
Self-citationUmemura, N., Saio, M., Suwa, T., Kitoh, Y., Bai, J., Nonaka, K., Ouyang, G.-F., Okada, M., Balazs, M., Adany, R., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0907611 · Cited by 346
Al-Khami, A. A., Zheng, L., Del Valle, L., Hossain, F., Wyczechowska, D., Zabaleta, J., Sanchez, M. D., Dean, M. J., Rodriguez, P. C., & Ochoa, A. C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344804 · Cited by 346
Chow, A., Zhou, W., Liu, L., Fong, M. Y., Champer, J., Van Haute, D., Chin, A. R., Ren, X., Gugiu, B. G., Meng, Z., et al. (2014) · Scientific Reports · doi:10.1038/srep05750 · Cited by 345
TCR ζ-chain downregulation: curtailing an excessive inflammatory immune response
Baniyash, M. (2004) · Nature Reviews Immunology · doi:10.1038/nri1434 · Cited by 344
Iclozan, C., Antonia, S., Chiappori, A., Chen, D.-T., & Gabrilovich, D. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1396-8 · Cited by 317
Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells
Nagaraj, S., & Gabrilovich, D. I. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6229 · Cited by 305
The regulation of MMP targeting to invadopodia during cancer metastasis
Jacob, A., & Prekeris, R. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00004 · Cited by 299
Combadiere, C., Ahuja, S. K., Lee Tiffany, H., & Murphy, P. M. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.1.147 · Cited by 292
Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
Wesolowski, R., Markowitz, J., & Carson, W. E. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-10 · Cited by 291
Recent advances on the role of tumor exosomes in immunosuppression and disease progression
Filipazzi, P., Bürdek, M., Villa, A., Rivoltini, L., & Huber, V. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.005 · Cited by 283
CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
Velasco-Velázquez, M., Jiao, X., De La Fuente, M., Pestell, T. G., Ertel, A., Lisanti, M. P., & Pestell, R. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3917 · Cited by 282
Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment
Ridder, K., Sevko, A., Heide, J., Dams, M., Rupp, A.-K., Macas, J., Starmann, J., Tjwa, M., Plate, K. H., Sültmann, H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008371 · Cited by 276
Self-citationMyeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy
Draghiciu, O., Lubbers, J., Nijman, H. W., & Daemen, T. (2015) · OncoImmunology · doi:10.4161/21624011.2014.954829 · Cited by 274
Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
A chemokine receptor antagonist inhibits experimental breast tumor growth.
Robinson, S. C., Scott, K. A., Wilson, J. L., Thompson, R. G., Proudfoot, A. E. I., & Balkwill, F. R. (2003) · PubMed · Cited by 259
Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., & Umansky, V. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202781 · Cited by 246
Self-citationBretz, N. P., Ridinger, J., Rupp, A.-K., Rimbach, K., Keller, S., Rupp, C., Marmé, F., Umansky, L., Umansky, V., Eigenbrod, T., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512806 · Cited by 245
Self-citationExosomes: The Messengers of Health and Disease
Isola, A. L., & Chen, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160825160421 · Cited by 223
Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., & Ullenhag, G. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1037-z · Cited by 219
Circulating and tumor‐infiltrating myeloid cell subsets in patients with bladder cancer
Eruslanov, E., Neuberger, M., Daurkin, I., Perrin, G. Q., Algood, C., Dahm, P., Rosser, C., Vieweg, J., Gilbert, S. M., & Kusmartsev, S. (2012) · International Journal of Cancer · doi:10.1002/ijc.26123 · Cited by 205
T Cell Apoptosis by Kynurenines
Fallarino, F., Grohmann, U., Vacca, C., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_21 · Cited by 204
Sade-Feldman, M., Kanterman, J., Klieger, Y., Ish-Shalom, E., Olga, M., Saragovi, A., Shtainberg, H., Lotem, M., & Baniyash, M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3104 · Cited by 201
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
Self-citationMyeloid‐derived suppressor cells: Important contributors to tumor progression and metastasis
Safarzadeh, E., Orangi, M., Mohammadi, H., Babaie, F., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26075 · Cited by 177
Myeloid-Derived Suppressor Cells Prevent Type 1 Diabetes in Murine Models
Yin, B., Ma, G., Yen, C.-Y., Zhou, Z., Wang, G. X., Divino, C. M., Casares, S., Chen, S.-H., Yang, W.-C., & Pan, P.-Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903636 · Cited by 170
Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T. J., Utikal, J., & Umansky, V. (2015) · International Journal of Cancer · doi:10.1002/ijc.29297 · Cited by 169
Self-citationTumor Microenvironment and Myeloid-Derived Suppressor Cells
Umansky, V., & Sevko, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0126-7 · Cited by 166
Self-citationKanterman, J., Sade-Feldman, M., Biton, M., Ish-Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Self-citationSinha, P., Chornoguz, O., Clements, V. K., Artemenko, K. A., Zubarev, R. A., & Ostrand‐Rosenberg, S. (2011) · Blood · doi:10.1182/blood-2010-11-321752 · Cited by 158
de Coaña, Y. P., Poschke, I. C., Gentilcore, G., Mao, Y., Nystrom, M. L., Hansson, J., Masucci, G. V., & Kiessling, R. W. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0016 · Cited by 146
The multifaceted nature of retinoid transport and metabolism
(2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2014.05.04 · Cited by 125
CALLEA, M., Albiges, L. K., Gupta, M., Cheng, S., Genega, E. M., Fay, A. P., Song, J., Carvo, I., Bhatt, R. S., Atkins, M. B., et al. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.1158/2326-6066 · Cited by 125
Berger, K., & Pu, J. J. (2017) · Gene · doi:10.1016/j.gene.2017.09.050 · Cited by 120
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., Scheper, R. J., Gerritsen, W. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0031-3 · Cited by 112
Ray, A., Chakraborty, K., & Ray, P. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00052 · Cited by 108
Kodera, Y., Katanasaka, Y., Kitamura, Y., Tsuda, H., Nishio, K., Tamura, T., & Koizumi, F. (2011) · Breast Cancer Research · doi:10.1186/bcr2903 · Cited by 107
Chen, H.-M., Ma, G., Gildener‐Leapman, N., Eisenstein, S. G., Coakley, B. A., Ozao, J. J., Mandeli, J., Divino, C. M., Schwartz, M., Sung, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2742 · Cited by 105
Meirow, Y., Kanterman, J., & Baniyash, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00523 · Cited by 99
Myeloid cell population dynamics in healthy and tumor-bearing mice
Ueha, S., Shand, F. H. W., & Matsushima, K. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.03.003 · Cited by 97
Hassel, J. C., Jiang, H., Bender, C., Winkler, J. K., Sevko, A., Shevchenko, I., Halama, N., Dimitrakopoulou‐Strauss, A., Haefeli, W. E., Jäger, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326440 · Cited by 97
Self-citationCCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma
Umansky, V., Blattner, C., Gebhardt, C., & Utikal, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1988-9 · Cited by 96
Self-citationZhang, Q., Hossain, D. M. S., Duttagupta, P. A., Moreira, D., Zhao, X., Won, H., Buettner, R., Nechaev, S., Majka, M., Zhang, B., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665604 · Cited by 92
Spinetti, T., Spagnuolo, L., Mottas, I., Secondini, C., Treinies, M., Rüegg, C., Hotz, C., & Bourquin, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1230578 · Cited by 92
Myeloid-derived suppressor cells and tumor escape from immune surveillance
Umansky, V., Blattner, C., Fleming, V., Hu, X., Gebhardt, C., Altevogt, P., & Utikal, J. S. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0597-6 · Cited by 82
Self-citationLin, S., Wang, J., Wang, L., Wen, J., Guo, Y., Qiao, W., Zhou, J., Xu, G., & Zhi, F. (2017) · Europe PMC (PubMed Central) · Cited by 82
Hypoxia-driven immunosuppression contributes to the pre-metastatic niche
Sceneay, J., Parker, B. S., Smyth, M. J., & Möller, A. (2012) · OncoImmunology · doi:10.4161/onci.22355 · Cited by 80
Energy metabolic pathways control the fate and function of myeloid immune cells
Al-Khami, A. A., Rodríguez, P. C., & Ochoa, A. C. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.1vmr1216-535r · Cited by 80
Shen, P., Wang, A., He, M., Wang, Q., & Zheng, S. (2013) · Hepatology Research · doi:10.1111/hepr.12167 · Cited by 67
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities
Kortylewski, M., & Moreira, D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1966-2 · Cited by 67
Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult
Loftus, T. J., Mohr, A. M., & Moldawer, L. L. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000395 · Cited by 63
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Baniyash, M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1849-y · Cited by 62
Hardy, L., Wick, D. A., & Webb, J. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.5956 · Cited by 56
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 56
Hansen, G. L., Gaudernack, G., Brunsvig, P. F., Cvancarova, M., & Kyte, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1766-5 · Cited by 50
Izhak, L., Wildbaum, G., Weinberg, U., Shaked, Y., Alami, J., Dumont, D., Stein, A., & Karin, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902725 · Cited by 41
Izhak, L., Wildbaum, G., Zohar, Y., Anunu, R., Klapper, L. N., Elkeles, A., Seagal, J., Yefenof, E., Ayalon-Soffer, M., & Karin, N. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802746 · Cited by 30
Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment
Pan, W., Sun, Q., Wang, Y., Wang, J., Cao, S., & Ren, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3363-9 · Cited by 11
Cited by
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Groth, C., Hu, X., Weber, R., Fleming, V., Altevogt, P., Utikal, J., & Umansky, V. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0333-1 · Cited by 839
Self-citationMDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Metadata
- Authors
- Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-03-02
- Volume
- 9
- Pages
- 398-398
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2793492950
- Cited by
- 443
- References
- 110
- FWCI
- 24.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.